C
CellVoyant
An AI-first biotechnology company with a mission to create novel stem cell-based therapies for chronic diseases
About CellVoyant
CellVoyant is a biotechnology startup that leverages artificial intelligence (AI) to develop novel stem cell-based therapies for chronic diseases. The company operates in the biotech market, specifically focusing on stem cell research and therapy. Their unique approach combines cell biology, computer vision, engineering, and machine learning to predict and optimize stem cell differentiation, which essentially means controlling the development of stem cells into other cell types. This ability to manufacture any cell and tissue in the body at scale has the potential to revolutionize the treatment of chronic diseases.
Read full description
CellVoyant's clients are primarily patients suffering from chronic diseases that could benefit from stem cell therapies. The company's business model revolves around developing and commercializing its AI-driven stem cell technology. They generate revenue by creating and selling their innovative therapies, which are designed to be robust, controllable, efficient, and safe.
The company is backed by venture capital firms that were early investors in AI pioneer DeepMind, AI-first drug discovery companies Exscientia and Recursion, and self-driving challenger Wayve. They also have the support of the founder/CEO of Abcam, a company that pioneered the antibody business.
In summary, CellVoyant is a promising startup that is harnessing the power of AI to revolutionize stem cell therapies. Their innovative approach could potentially provide a more efficient and effective way to treat chronic diseases, making them a company to watch in the biotech sector.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Bristol, United Kingdom
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 70.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Core AI, Spinout, Biotech and Pharma, AI Drug Discovery, Techbio, CompBio
- Technology
- Artificial Intelligence, Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Jan 2024 | $10M | $40M | Octopus Crypto Capital · Horizons Ventures · Verve Ventures · Air Street Capital | ↗ |
| SPINOUTOther financing | Aug 2021 | $0 | — | University of Bristol | ↗ |
Growth signals
Latest recorded traffic for CellVoyant is 4.1K monthly website visits, up 70.8% over the last three months. CellVoyant's team declined 15.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Octopus Crypto Capital
Horizons Ventures
Verve Ventures
Air Street Capital
Other known investors1 additional known investor
University of Bristol
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CellVoyant on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CellVoyant’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.